Eisai to ask Australia to reconsider rejection of Alzheimer's drug Leqembi
Australia’s regulatory agency rejected Biogen and Eisai’s Alzheimer’s drug Leqembi, noting that the drug’s efficacy doesn’t outweigh the safety risks.
Australia’s Therapeutic Goods Administration …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.